Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders - BIVV

Thursday, 01 February 2018 03:00 PM

Levi & Korsinsky, LLP

Topic:

NEW YORK, NY / ACCESSWIRE / February 1, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Bioverativ Inc. ("Bioverativ" or the "Company") (NASDAQ: BIVV) stock prior to January 22, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Bioverativ Inc. to Sanofi for $105 per share. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/bioverativ-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Bioverativ breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Sanofi is underpaying for Bioverativ shares, thus unlawfully harming Bioverativ shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Back to newsroom
Back to Newsroom
Share by: